ArticleCommunications biology2025
A reference-guided iterative approach to polish the nanopore sequencing basecalling for therapeutic RNA quality control.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
Nucleotide modifications deviate nanopore sequencing readouts, therefore generating artifacts during the basecalling of sequence backbones. Here, we present a reference-guided, iterative approach to polish modification-disturbed basecalling results. We show that such an approach is uniquely suitable for training biomolecule-specific high-accuracy basecallers, by improving the basecalling of both artificially-synthesized and real-world molecules. With demonstrated efficacy and reliability, we exploit the approach to precisely basecall therapeutic RNAs consisting of artificial or natural modifications. We first analyzed vaccine mRNAs, which are artificially modified to promote stability and reduce immunogenicity. Specifically, we quantified the sequence purity and integrity, the two most important quality metrics to be controlled during mRNA vaccine production. We also analyzed BioRNAs, which are human tRNA-based carriers for therapeutic RNA interference (RNAi) agents. Specifically, we examined modification hotspots, which are naturally incorporated in vivo during BioRNA production and essential for therapeutic efficacy. Our analysis expands the scope of therapeutic RNA quality control, from the conventional sequence-level to the current modification status-level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.